Muscle NAD+ depletion and Serpina3n as molecular determinants of murine cancer cachexia – the effects of blocking myostatin and activins

Show full item record



Hulmi , J J , Penna , F , Pöllänen , N , Nissinen , T A , Hentila , J , Euro , L , Lautaoja , J H , Ballarò , R , Soliymani , R , Baumann , M , Ritvos , O , Pirinen , E & Lalowski , M 2020 , ' Muscle NAD+ depletion and Serpina3n as molecular determinants of murine cancer cachexia – the effects of blocking myostatin and activins ' , Molecular metabolism , vol. 41 , 101046 .

Title: Muscle NAD+ depletion and Serpina3n as molecular determinants of murine cancer cachexia – the effects of blocking myostatin and activins
Author: Hulmi, Juha J.; Penna, Fabio; Pöllänen, Noora; Nissinen, Tuuli A.; Hentila, Jaakko; Euro, Liliya; Lautaoja, Juulia H.; Ballarò, Riccardo; Soliymani, Rabah; Baumann, Marc; Ritvos, Olli; Pirinen, Eija; Lalowski, Maciej
Contributor organization: CAMM - Research Program for Clinical and Molecular Metabolism
Faculty of Medicine
University of Helsinki
Research Programs Unit
STEMM - Stem Cells and Metabolism Research Program
Department of Biochemistry and Developmental Biology
Helsinki Institute of Life Science HiLIFE
Marc Baumann / Principal Investigator
University Management
Department of Physiology
Growth factor physiology
Eija Pirinen / Principal Investigator
Date: 2020-11
Language: eng
Number of pages: 13
Belongs to series: Molecular metabolism
ISSN: 2212-8778
Abstract: Objective Cancer cachexia and muscle loss are associated with increased morbidity and mortality. In preclinical animal models, blocking activin receptor (ACVR) ligands has improved survival and prevented muscle wasting in cancer cachexia without an effect on tumour growth. However, the underlying mechanisms are poorly understood. The present study aimed to identify cancer cachexia and soluble ACVR (sACVR) administration-evoked changes in muscle proteome. Methods Healthy and C26 tumour-bearing (TB) mice were treated with recombinant sACVR. The sACVR or PBS control were administered either prior to the tumour formation or by continued administration before and after tumour formation. Muscles were analysed by quantitative proteomics with further examination of mitochondria and nicotinamide adenine dinucleotide (NAD+) metabolism. To complement the first prophylactic experiment, sACVR (or PBS) was injected as a treatment following tumour cell inoculation. Results Muscle proteomics in TB cachectic mice revealed downregulated signatures for mitochondrial oxidative phosphorylation (OXPHOS) and increased acute phase response (APR). These were accompanied by muscle NAD+ deficiency, alterations in NAD+ biosynthesis including downregulation of nicotinamide riboside kinase 2 (Nrk2), and decreased muscle protein synthesis. The disturbances in NAD+ metabolism and protein synthesis were rescued upontreatment with sACVR. Across the whole proteome and APR in particular, Serpina3n represented the most upregulated protein and the strongest predictor of cachexia. However, the increase in Serpina3n expression associated with increased inflammation rather than decreased muscle mass and/or protein synthesis. Conclusions We present here an evidence implicating disturbed muscle mitochondrial OXPHOS proteome and NAD+ homeostasis in experimental cancer cachexia. Treatment of tumour-bearing mice with a blocker of activin receptor ligands restores depleted muscle NAD+ and Nrk2 as well as decreased muscle protein synthesis. These results point out putative new treatment therapies for cachexia. Our results also reveal that although acute phase protein Serpina3n may serve as a predictor of cachexia, it more likely reflects a condition of elevated inflammation.
Subject: 318 Medical biotechnology
Activin receptor
Cancer cachexia
Cancer cachexia
Activin receptor
Peer reviewed: Yes
Rights: cc_by
Usage restriction: openAccess
Self-archived version: acceptedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S2212877820301204_main.pdf 2.458Mb PDF View/Open
Muscle_NAD_depl ... myostatin_and_activins.pdf 5.355Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record